Carotid bodies are sensory organs for monitoring arterial oxygen and CO2. Previous studies have shown that chemoreceptor tissue contains substance P (SP) and exogenously administered SP augments chemosensory discharge.
In the present study, we examined the physiological importance of SP in carotid body chemoreception by using a selective nonpeptide SP [neurokinin (NK) 1] receptor antagonist CP-96, 345 . In experiments performed on anesthetized cats, sensory discharge was recorded from the carotid body in situ. To control for alterations in blood flow, additional studies were conducted on the carotid body in vitro. In in vivo studies, close carotid body (intraarterial) administration of CP-96,345 attenuated the sensory response to hypoxia in a dose-dependent manner with 73% of the response abolished at doses of 0.3-0.6 mg/kg. Comparable doses of the (2R,3R)-enantiomer had no effect on hypoxia-induced excitation, indicating that the effect of CP-96,345 was not due to nonspecific action. In contrast, the carotid body response to high CO2 was not affected by CP-96,345, implying that only the hypoxic response is mediated by NK-1 receptor and confirming that the effect of the SP antagonist was not due to nonspecific actions. Marked attenuation of the sensory response to hypoxia was also obtained in the carotid body in vitro, suggesting that the effects of the NK-1 antagonist were not secondary to cardiovascular changes. These results demonstrate that CP-96,345 attenuates or abolishes the chemosensory response to hypoxia but not to CO2 and suggest that SP mediates the hypoxia-induced sensory excitation in the cat carotid body via NK-1 receptor activation.
Carotid bodies are sensory organs that detect changes in arterial oxygen and CO2. Reflexes arising from the carotid body are critical for maintaining the ventilatory and circulatory homeostasis during altered blood gas conditions. The sensory receptor complex is composed of type I cells that receive sensory innervation from the carotid sinus nerve. Hypoxemia (low arterial oxygen) and high CO2 (hypercapnia) increase the sensory discharge of the carotid bodies. The current hypothesis is that the type I cells ( (2) postulated that glomus cells secrete a peptide that may be necessary for chemosensory excitation during hypoxia. It is now well established that glomus cells contain several peptides including enkephalins (3), atrial natriuretic peptide (4), and the tachykinin substance P (SP) (5) . Enkephalins are inhibitory to carotid body activity, as they are elsewhere in the nervous system (1). Atrial natriuretic peptide, while
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. having no effect alone, inhibits the sensory excitation by hypoxia (4) . On the other hand, SP stimulates the carotid bodies of cats (5-7) and rats (8) . Moreover, systemic administration of SP potentiates the hypoxic ventilatory drive in awake human subjects, an effect that was attributed to its stimulatory action on carotid bodies (9) . Thus far, these studies suggest that SP is an excitatory peptide to the carotid body in experimental animals and possibly in humans.
Biological actions of SP are selectively mediated by neurokinin (NK) 1 receptors that have been cloned and biochemically characterized (10) . Peptidyl antagonists have been used to examine the physiological role(s) of SP (11, 12) . However, these compounds have some inherent problems that make them suboptimal for in vivo studies. For To maintain constant blood gases, anesthetized animals were artificially ventilated after paralyzing them with Flaxedil (3-4 mg/kg; i.v.). The dose-dependent effects of CP-96,345 on carotid body responses to hypoxia and CO2 were examined in seven cats. The protocols were as follows. ( Step 1) The effects of three levels of arterial Po2 were examined on chemoreceptor activity by ventilating the animals with 100%o, 21%, and 12% 02, while maintaining arterial Pco2 at 33 ± 4 mmHg (1 mmHg = 133 Pa). After challenging the animal with 12% 02, ventilation was switched back to 100%O 02. Subsequently, carotid body responses to hyperoxic hypercapnia was examined by ventilating the animals with 7% C02/93% 02. Each gas challenge was maintained for 5 min to ensure steady-state blood gas values. Arterial blood samples were collected during the last minute of each gas challenge for analysis of arterial Po2, Pco2, and pH. The time taken to accomplish Step 1 was 20-30 min. ( Step 2) The above-described protocols with hypoxia in Step I were repeated after intracarotid infusion of (i) saline (vehicle control) and (ii) of CP-96,345 at 0.02, 0.08, 0.3, and 0.6 mg/kg. The volume of the infusate was 3 ml given over a period of 10 min. Either saline or the antagonist was infused while the animal was ventilated with 100% 02. Blood pressure decreased during the infusion of the antagonist. Within 5 min after terminating the infusion, arterial pressure returned to preinjection values. Therefore, after each infusion, a 5-min period was allowed so that the hypoxic responses could be compared at comparable levels of blood pressure. The time required for the protocols in Step 2, including the infusion of antagonist, waiting period, and gas challenges was 120-150 min. ( Step 3) Carotid body responses to hyperoxic hypercapnia (7% C02/93% 02; 5 min) were examined only with those doses of CP-96,345 that markedly attenuated the response to hypoxia. On average, 200 min was required to complete the protocols described in Steps 1-3. To assess viability of the preparation within this period, the hypoxic response was monitored with infusion of saline alone at intervals used for administration of different doses of the antagonist in two additional cats.
The effect of the (2R,3R)-enantiomer was examined at doses comparable to those of CP-96,345 that antagonized the response to hypoxia in another six cats. The protocols for examining the effects of hypoxia were the same as above.
In Vitro Studies. The carotid body, together with the carotid sinus nerve, was excised from anesthetized cats (n = 13 carotid bodies). After removing the connective tissue, carotid body was placed in a Perspex chamber having two compartments, A and B, separated by a small opening. The carotid sinus nerve was desheathed, placed on a platform in chamber B, and covered with warm mineral oil. The carotid body in chamber A was superfused with Krebs solution at a rate of 2-3 ml/min. Temperature (Fig. 1) . However, the effective doses of the antagonist varied somewhat in different animals. In the example shown in Fig. 1 , hypoxic excitation was nearly abolished at a dose of 0.6 mg/kg. Average data from seven experiments showed that 73% of the hypoxic response was abolished by the antagonist at 0.3-0.6 mg/kg (Fig. 2) .
Chemoreceptor responses to three levels of arterial oxygen were examined with maximal doses of the antagonist (i.e., 0.3-0.6 mg/kg; Fig. 3A ). Sensory discharge during hyperoxia (100% 02) was not affected by the antagonist. However, the increase in discharge frequencies during 21% and 12% 02 ventilation was significantly reduced by the antagonist. In two additional cats, the chemosensory response to three levels of Po2 was monitored after infusions of saline (four times) instead of different doses of the antagonist at the same time intervals. In both cats, the sensory response to 12% 02 was not affected by repeated saline infusions (for cat 1, control, +28 imp per sec; after fourth infusion of saline, +32 imp per sec and for cat 2, control, +22 imp per sec; after fourth infusion of saline, + 19 imp per sec). These observations suggest that infusion of saline alone did not result in deterioration of sensory response to hypoxia. Hypoxic response did not return to control values within 60-90 min in four cats so tested.
CP-96,344 is the (2R,3R)-enantiomer of CP-96,345 and contains at least 104 less antagonist activity (13) . As can be seen from Fig. 4 , elevating the arterial Pco2 (from 33 ± 4 to 51 ± 2 mmHg) stimulated the carotid body. After administration of SP antagonist (0.3-0.6 mg/kg), CO2 response was increased by 15% in one, decreased by 10% in two, and unaffected in three other cats. Thus, overall responses to CO2 were not significantly affected by SP antagonist at doses of 0.3-0.6 mg/kg (control, +3.7 ± 1.1 imp per sec; antagonist, +3.2 ± 1.0 imp per sec; P > 0.05; n = 6).
Effect of NK-1 Antagonist on Carotid Body Response to Hypoxia in Vitro. To establish that the effects of the antagonist were not secondary to cardiovascular changes, a second series of experiments were performed on isolated superfused carotid bodies (n = 7). An example of an experiment illustrating the effect of CP-96,345 on the carotid body response to hypoxia from two identifiable chemoreceptor units (large and a smaller spike) is presented in Fig. 5 . As can be seen, discharge frequency of the larger unit increased and was maintained during the hypoxic challenge. The activity of the A 50-1 other unit with smaller spike amplitude does not appear at the onset of hypoxia but was recruited during hypoxia and its discharge frequency was markedly increased in the last minute of hypoxia. SP antagonist nearly abolished the discharge frequency of the smaller unit and diminished the response of the larger unit. Overall magnitude of the sensory response to hypoxia was reduced by SP antagonist in a dose-dependent manner (Figs. 5 and 6 ). Moreover, the chemoreceptor response tends to build up slowly by increasing the dose of the antagonist (Fig. 5) . Average results have shown that maximally effective concentrations of the antagonist in in vitro studies ranged between 0.9 and 1.8 ,uM (Fig.  6) Besides neuropeptides, the carotid body contains biogenic amines such as dopamine, norepinephrine, and acetylcholine, often released during hypoxia (1) . Blockade of NK-1 receptors alone markedly affecting the sensory excitation by hypoxia raises the question of the importance of other neurochemicals in oxygen chemoreception. It should, however, be recalled that increased sensory discharge of the carotid body is maintained during the entire period of hypoxia, so that the central nervous system is continuously being informed about the status of arterial oxygenation (1). Neurochemicals in the carotid body should not only produce excitation but also maintain the augmented sensory activity during the entire period of hypoxic challenge. From the present results, it appears that SP is associated with the sensory excitation by hypoxia. It is conceivable that other neurochemicals that are inhibitory to the carotid body activity (e.g., dopamine) may prevent the over excitation and thus sustain the increased sensory discharge.
The mechanism(s) by which SP stimulates the carotid body and its site(s) of action within the chemoreceptor tissue cannot be ascertained from the present results. It is conceivable that one likely site of SP action is the afferent nerve ending. In addition, SP might act presynaptically on type I cells and enhance the release of other neurotransmitters, as it does elsewhere in the peripheral nervous system (16) . Such interactions of SP with other transmitter molecules might be important for regulation of the chemosensory response to hypoxia. Further experiments are necessary to elucidate the site and mechanism(s) of actions of SP in the carotid body.
